NASDAQ
ALKS

Alkermes Plc

Drug Manufacturers-Specialty & Generic
Healthcare

Prices are adjusted according to historical splits.

Alkermes Plc Stock Price

Vitals

Today's Low:
$29.45
Today's High:
$30.76
Open Price:
$29.46
52W Low:
$21.75
52W High:
$32.79
Prev. Close:
$29.52
Volume:
2366559

Company Statistics

Market Cap.:
$4.47 billion
Book Value:
6.35
Revenue TTM:
$1.11 billion
Operating Margin TTM:
-12.8%
Gross Profit TTM:
$893.69 million
Profit Margin:
-14.24%
Return on Assets TTM:
-4.46%
Return on Equity TTM:
-14.68%

Company Profile

Alkermes Plc had its IPO on 1991-07-16 under the ticker symbol ALKS.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Alkermes Plc has a staff strength of 2,280 employees.

Stock update

Shares of Alkermes Plc opened at $29.46 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $29.45 - $30.76, and closed at $30.63.

This is a +3.76% increase from the previous day's closing price.

A total volume of 2,366,559 shares were traded at the close of the day’s session.

In the last one week, shares of Alkermes Plc have increased by +4.65%.

Alkermes Plc's Key Ratios

Alkermes Plc has a market cap of $4.47 billion, indicating a price to book ratio of 4.0367 and a price to sales ratio of 3.6432.

In the last 12-months Alkermes Plc’s revenue was $1.11 billion with a gross profit of $893.69 million and an EBITDA of $-64403000. The EBITDA ratio measures Alkermes Plc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Alkermes Plc’s operating margin was -12.8% while its return on assets stood at -4.46% with a return of equity of -14.68%.

In Q4, Alkermes Plc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 6.1%.

Alkermes Plc’s PE and PEG Ratio

Forward PE
588.2353
Trailing PE
0
PEG
-1057.29

Its diluted EPS in the last 12-months stands at $-0.99 per share while it has a forward price to earnings multiple of 588.2353 and a PEG multiple of -1057.29. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alkermes Plc’s profitability.

Alkermes Plc stock is trading at a EV to sales ratio of 3.5657 and a EV to EBITDA ratio of -72.8504. Its price to sales ratio in the trailing 12-months stood at 3.6432.

Alkermes Plc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.96 billion
Total Liabilities
$497.74 million
Operating Cash Flow
$27.74 million
Capital Expenditure
$31.18 million
Dividend Payout Ratio
0%

Alkermes Plc ended 2024 with $1.96 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.96 billion while shareholder equity stood at $1.04 billion.

Alkermes Plc ended 2024 with $0 in deferred long-term liabilities, $497.74 million in other current liabilities, 1690000.00 in common stock, $-1699285000.00 in retained earnings and $92.87 million in goodwill. Its cash balance stood at $292.47 million and cash and short-term investments were $608.47 million. The company’s total short-term debt was $18,722,000 while long-term debt stood at $290.27 million.

Alkermes Plc’s total current assets stands at $1.13 billion while long-term investments were $131.61 million and short-term investments were $315.99 million. Its net receivables were $296.90 million compared to accounts payable of $220.09 million and inventory worth $181.42 million.

In 2024, Alkermes Plc's operating cash flow was $27.74 million while its capital expenditure stood at $31.18 million.

Comparatively, Alkermes Plc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$30.63
52-Week High
$32.79
52-Week Low
$21.75
Analyst Target Price
$33.2

Alkermes Plc stock is currently trading at $30.63 per share. It touched a 52-week high of $32.79 and a 52-week low of $32.79. Analysts tracking the stock have a 12-month average target price of $33.2.

Its 50-day moving average was $29.32 and 200-day moving average was $28.44 The short ratio stood at 6.96 indicating a short percent outstanding of 0%.

Around 176.7% of the company’s stock are held by insiders while 10316% are held by institutions.

Frequently Asked Questions About Alkermes Plc

The stock symbol (also called stock or share ticker) of Alkermes Plc is ALKS

The IPO of Alkermes Plc took place on 1991-07-16

Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)

Last Price
Chg
Chg%
$361.85
-7.85
-2.12%
$18.14
0
0%
$15.02
0.16
+1.08%
$389.15
-7.55
-1.9%
$24.31
-0.02
-0.08%
$117.41
0.92
+0.79%
$0.44
0.01
+1.55%
$42.1
0.56
+1.35%
Caredx Inc (CDNA)
$8.5
0.17
+2.04%
Jyothy Labs Limited (JYOTHYLAB)
$347.9
-17.7
-4.84%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA/ XEPLION for the treatment of schizophrenia and schizoaffective disorder; INVEGA TRINZA, TREVICTA, and HAFYERA/BYANNLI to treat schizophrenia; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Address

Connaught House, Dublin, Ireland, 4